A comprehensive view of men's health issues. This page highlights a small sample of our full coverage.
For real-time access, please log in to your Health Care Sector Market Intelligence Service.
University of Michigan researchers have developed a urine-based test, MyProstateScore2.0, that differentiates between slow growing and aggressive forms of prostate cancer; the test could reduce unnecessary biopsies by around 41%
Published:
April 19, 2024
by University of Michigan Institute for Healthcare Policy & Innovation
|
Olympus reports positive policy changes by commercial payers is extending coverage for iTind, its minimally invasive treatment for benign prostatic hyperplasia; policy updates may affect up to 27 million enrollees in the US
Published:
April 15, 2024
by Olympus America Inc.
|
Arvinas secures over US$1.0B deal with Novartis for the development and commercialization of its second-gen prostate cancer treatment ARV-766; Arvinas is also eligible for an additional US$1.01B in development, regulatory, and commercial milestones
Published:
April 11, 2024
by Invezz
|
Novartis to file for Pluvicto pre-taxane label expansion in H2 2024 after updated survival results show hazard ratio less than 1.0; full results to be presented at upcoming medical congress
Published:
April 05, 2024
by Contify Life Science News
|
American Cancer Society and Pfizer fund US$15.0M project 'Change the Odds' for underserved communities to address disparity in cancer care; program to focus on breast and prostate cancer
Published:
February 06, 2024
by Managed Healthcare Executive
|
Ask us about our Health Care Sector market view